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Normalization of
Valve Function After
Failed Fibrinolytic Therapy
for Left-Sided Prosthetic
Valve Thrombosis
Left-sided mechanical prosthetic valve thrombosis
(PVT) is a life-threatening condition frequently seen
in developing countries (1). Although urgent surgery
is more effective (2,3), ﬁbrinolytic therapy (FT) is the
most commonly used treatment in these countries.
About one-third of patients treated with FT do not
have successful restoration of valve function (2–4).
Although all such patients are considered for addi-
tional surgery, it is often delayed in resource-poor
settings. It is our experience, supported by anec-
dotal reports (5), that residual valve dysfunction may
normalize uneventfully while the patient receives
oral anticoagulation. However, the rate of such an
occurrence is unknown because there are no pro-
spective studies of patients with residual valve
dysfunction awaiting surgery.
In this single-center, prospective, observational
study, we enrolled patients undergoing FT for left-
sided PVT if they had either a failed or partial
response (4). We excluded patients who were hemo-
dynamically unstable or had a major complication
requiring urgent intervention. All patients were
referred for surgery and were followed up 1 month
after discharge and subsequently at 3-month in-
tervals. At each follow-up visit, patients underwent
clinical, echocardiographic, and ﬂuoroscopic evalua-
tion. All patients gave written informed consent,
and the institutional ethics committee approved the
study protocol.
The primary outcome was the occurrence of
spontaneous normalization of valve function, deﬁned
as complete normalization of valve leaﬂet motion
on ﬂuoroscopy and valve gradients on echocardi-
ography. We determined the Kaplan-Meier rate
of occurrence of the primary outcome and evalu-
ated potential predictors by use of Cox regression.
We also determined the rate of occurrence of majoradverse events (a composite of death, stroke, tran-
sient ischemic attack, or non–central nervous system
embolism, major bleeding, and recurrent PVT). All
analyses were performed with the use of Stata 13
(StataCorp, College Station, Texas).
Of the 122 patients who received FT for left-sided
PVT between February 1, 2010 and January 31, 2012,
31 patients were eligible for enrollment (Table 1).
Streptokinase was the most commonly used agent for
ﬁbrinolysis. All except one patient received at least
72 h of streptokinase or a full dose of tissue plas-
minogen activator. All patients improved with FT,
and nearly 90% (25 of 28) were in New York Heart
Association functional class I or II at ﬁrst follow-up.
Of the 31 patients, 1 died and 4 had restoration of
valve function in-hospital, possibly as the result of
delayed effects of the ﬁbrinolytic infusion. Three
patients (12.5%) underwent elective redo valve
replacement, and 2 were lost to follow-up. Eleven of
the remaining 24 patients (45.8%) showed sponta-
neous normalization of valve function over 15
person-years of follow-up (0.73/person-years; 95%
conﬁdence interval [CI]: 0.41 to 1.33). The mean time
to valve opening was 3 months, with none opening
beyond 6 months. Fewer patients had subtherapeutic
international normalized ratios (INRs) at follow-up
(21% vs. 65% at presentation, p ¼ 0.006), and the
average INR during follow-up was higher than at
the time of presentation (3.1  0.6 vs. 2.5  1.6;
p ¼ 0.0059; n ¼ 23). The percentage of reduction in
transvalvular gradients with FT (hazard ratio, 4.80;
95% CI: 0.65 to 35.15; p ¼ 0.12) and the average INR
during follow-up (hazard ratio, 3.45; 95% CI: 0.84 to
14.19; p ¼ 0.086) were associated with the occurrence
of the primary outcome, but these associations were
not statistically signiﬁcant.
Seven patients had eight major adverse events.
Four events occurred in the hospital (1 death, 2 non-
fatal intracranial bleeds, and 1 stroke) and were
attributable to ﬁbrinolytic therapy. After discharge
from the hospital, over a 27.8 person-year follow-up,
4 patients had 4 major adverse events (2 deaths, 1
recurrence of PVT, and 1 major bleed), at a rate of
0.14/person-years (95% CI: 0.05 to 0.38). The earliest
event occurred at 1 month and the last at 4 months.
There were no adverse events beyond 4 months of
follow-up. Overall, 6 of 10 (60%) patients who did not
TABLE 1 Baseline Characteristics and Response to
Fibrinolytic Therapy (N ¼ 31)
Age, yrs 28  9.6
Women 16 (51.6)
Time from valve replacement to PVT, months 32 (17.75, 71.75)
Mitral PVT 21 (67.7)
NYHA functional class III/IV 20 (64.5)
Subtherapeutic INR* 20 (69)
Previous valve thrombosis 6 (19.4)
Response to ﬁbrinolytic therapy
Pre- and post-treatment mitral EDG, mm Hg 14.3, 6.2†
Pre- and post-treatment mitral MDG, mm Hg 25.5, 12‡
Pre- and post-treatment aortic PSG, mm Hg 66.5, 39.5§
Pre- and post-treatment aortic MSG, mm Hg 38.2, 22.6k
Complete failure 18 (58.1)
Partial response 13 (41.9)
Values are mean  SD, n (%), or median (IQR). *Two patients did not have baseline
INR values. †p ¼ 0.00039. ‡p ¼ 0.000066. §p ¼ 0.017. kp ¼ 0.039.
EDG ¼ end-diastolic gradient; INR ¼ international normalized ratio; MDG ¼
mean diastolic gradient; MSG ¼ mean systolic gradient; NYHA ¼ New York Heart
Association; PSG ¼ peak systolic gradient.
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functional class had a major complication compared
with one of 19 (5.3%) who did improve (p ¼ 0.0026).
Reduction in valve gradients with FT did not correlate
with improvement in functional class and was not
associated with the occurrence of adverse outcomes.
This is the ﬁrst report to document the occur-
rence of spontaneous valve opening after failed FT.
In a review of 243 patients in 17 retrospective
studies with failed FT, Huang et al. (3) found that
follow-up information was not available in more
than 40% of patients even for assessment of 30-day
outcomes. None of the studies followed up patients
beyond 30 days. This information is relevant for
developing countries because many patients with
residual valve dysfunction do not undergo redo
surgery.
Though spontaneous restoration of valve function
was common, the rate of major adverse events during
follow-up was high. However, these events occurred
almost exclusively in patients (6 of 7) who were in
New York Heart Association functional class III or
those who had not improved in functional class with
FT. The magnitude of reduction in transvalvular
gradients, though predictive of spontaneous valve
opening, was not associated with either improve-
ment in functional class or the occurrence of adverse
events. Transvalvular gradients are dynamic and
are inﬂuenced by many variables, including heart
rate, and may misrepresent the degree of valve
dysfunction. However, these ﬁndings are based on a
small number of patients and must be interpreted
cautiously.In conclusion, residual valve dysfunction after
FT normalizes spontaneously in nearly one-half the
patients, but the risk of major adverse events is pro-
hibitively high, particularly among patients who do
not show improvement in functional class after FT.
Thus, these patients should be triaged for early redo
surgery irrespective of the reduction in transvalvular
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Atrial Fibrillation
Ablation in Patients
With Hypertrophic
CardiomyopathyLong-Term Outcomes and Clinical PredictorsAtrial ﬁbrillation (AF) is common in patients with
hypertrophic cardiomyopathy (HCM), present in 20%
to 25% (1). Radiofrequency (RF) ablation is a safe and
effective option for selected patients with symptom-
atic AF. However, its efﬁcacy in patients with HCM
has been less studied. AF in this group may have
different mechanisms and thus, catheter ablation
may have a different effect. We compared the
